Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents

Innovations in Clinical Neuroscience

Volumn 9, Issue 7-8, 2012, Pages 17-23

  Sheehan, John J ^a,b   Reilly, Kristin R ^a   Fu, Dong Jing ^a   Alphs, Larry ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antipsychotic; Long acting injectable; Oral; Peak to trough fluctuation

Indexed keywords

HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PALMITIC ACID; RISPERIDONE; ZUCLOPENTHIXOL;

CLINICAL STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; MAXIMUM PLASMA CONCENTRATION; REVIEW; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84867049043     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520.
2. Medori R, Mannaert E, Grunder G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol. 2006;16(4):233-240.
3. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33(2):298-304.
4. Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokineticpharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol. 2008;584(2-3):318-327.
5. Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol (Oxf). 2008;22(8):882-894.
6. Locatelli I, Kastelic M, Koprivsek J, et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur J Pharm Sci. 2010;41(2):289-298.
7. Yoshimura R, Ueda N, Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology. 2001;44(3):129-133.
8. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol. 2005;20(2):71-78.
9. Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs: an original patient data metaanalysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 2009;35(4):789-797.
10. Benet LZ, Kroeta DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbirg LE, Molinoff PB, et al (eds). Goodman & Gillman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:3-27.
11. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64:18-23.
12. Johnson DA. The side-effects of fluphenazine decanoate. Br J Psychiatry. 1973;123(576):519-522.
13. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitring in psychiatry. Pharmacopsychiatry. 2004;37(6):243-265.
14. Poulsen JH, Olesen OV, Larsen NE. Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Ther Drug Monit. 1994;16(2):155-159.
15. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel oncemonthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585-600.
16. ® Relprevv™ (olanzapine for extended release injectable suspension). 2011. Indianapolis, IN: Eli Lilly and Company.
17. ® (risperidone) long-acting injection. 2010. Titusville, NJ: Janssen Pharmaceuticals, Inc.
18. ® Decanoate (haloperidol decanoate injection). 2011. Titusville, NJ: Janssen Pharmaceuticals, Inc.
19. Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol. 1987;27(2):144-150.
20. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52:S13-S19.
21. Samtani MN, Haskins JT, Alphs L, et al. Maintenance dosing of oncemonthly (4-weekly) paliperidone palmitate in schizophrenia: Pharmacokinetic rationale based on population simulations 2009. Poster presented: Annual Meeting of The College of Psychiatric and Neurologic Pharmacists; April 19-22, 2009; Jacksonville, FL.
22. Mannaert E, Vermeulen A, Remmerie B, et al. Pharmacokinetic profile of longacting injectable risperidone at steady-state: comparison with oral administration. Encephale. 2005;31(5 Pt 1):609-615.
23. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177-193.
24. Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. (Oxf) 2010;24(7):1011-1018.
25. Johnson & Johnson Pharmaceutical Research and Development, LLC. Clinical study report SCH-101 EDMS-PSDB-2637921:5.0. Data on file.
26. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a secondgeneration antipsychotic. Int J Clin Pract. 2009;63(1):140-150.
27. ® (paliperidone palmitate) extended-release injectable suspension. 2011. Titusville, NJ: Janssen Pharmaceuticals, Inc.
28. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435-456.
29. ® (olanzapine) orally disintegrating tablets. 2011. Indianapolis, IN: Eli Lilly and Company.
30. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54(3):257-268.
31. ® (paliperidone) extendedrelease tablets. 2011. Titusville, NJ: Janssen Pharmaceuticals, Inc.
32. Bai YM, Ting CT, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, singleblind pharmacokinetic study. J Clin Psychiatry. 2007;68(8):1218-1225.
33. Yasui-Furukori N, Saito M, Nakagami T, et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol (Oxf). 2010;24(7):987-994.
34. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl). 2001;153(2):238-243.
35. Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005;255(4):261-268.
36. Klampfl K, Taurines R, Preuss A, et al. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry. 2010;43(2):58-65.
37. National Institute for Health and Clinical Excellence. Schizophrenia: The NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care - updated edition. National Institute for Health and Clinical Excellence Web site 2010. http://guidance.nice.org.uk/CG82. Accessed October 12, 2010.
38. Rossenu S, Crauwels H, Cleton A, et al. Comparison of the pharmacokinetics of an oral immediate-release and extendedrelease formulation of paliperidone in healthy subjects 2010. Poster presented at: Annual Meeting and Exposition or the American Association of Pharmaceutical Sciences; October 29-November 02, 2006; San Antonio, TX.
39. Canuso CM, Grinspan A, Kalali A, et al. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010;25(3):155-164.
40. Cleton A, Rossenu S, Crauwels H, et al. Assessment of the dose proportionality if paliperidone palmate 25,50,100 and 150 mg eq. a new long-acting injectable antipsychotic, following administration in the deltoid or gluteal muscles. Poster presented at: American Society of Clinical Pharmacology and Therapeutics: April 2-5, 2008; Orlando, Florida.
41. Johnson & Johnson Pharmaceutical Research and Development, LLC. Clinical study report PSY-1004 EDMS-PSDB-6213530:3.0. Data on file.